Zai Lab Ltd. Unsponsored ADR Stock News

ZLAB is continuing to grow revenues through its Chinese in-licensed strategy. Continuing growth of in-licensed programs is mixed, with imminent approvals in China but also termination of key studies. However, I think the market is pushing this further and further into "undervalued," given the narrowing losses and promise of their own pipeline projects.

Zai Lab Limited ( ZLAB ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christine Chiou - Senior VP & Head of Investor Relations Ying Du - Founder, Chairperson & CEO Rafael Amado - President and Head of Global Research & Development Joshua Smiley - President & COO Yajing Chen - Chief Financial Officer Conference Call Participants Jonathan Chang Anupam Rama - JPMorgan Ch...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and supported by a commercially profitable and scalable business in China,” ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2025: Jefferies Global Healthcare Conference in London Fireside Chat: Wednesday, November 19, 2025 at 8:30AM GMT Location: London Citi's 2025 Global Healthcare...

Zai Lab Limited (NASDAQ:ZLAB ) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development October 24, 2025 11:00 AM EDT Company Participants Rafael Amado - President and Head of Global Research & Development Joshua Smiley - President & COO Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Li Wang Watsek - Cantor Fitz...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an o...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast In...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and ...